News Ouro makes debut with $120m for autoimmune disease TCEs Ouro launches today with $120m in funding and a plan to develop bispecific antibody-based T cell engagers for autoimmune diseases.
Oncology ASCO 2024 - Matteo Levisetti ASCO 2024 marked the 10th anniversary of checkpoint inhibitors, which powerfully changed the nature of cancer immunotherapy.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.